NCT00781482 is a Phase 4 clinical trial of eszopiclone, zolpidem, placebo in Healthy, sponsored by Kettering Health Network.

Who is sponsoring NCT00781482?

NCT00781482 is sponsored by Kettering Health Network.

What drugs are being tested in NCT00781482?

Interventions in NCT00781482: eszopiclone, zolpidem, placebo.

Is NCT00781482 still recruiting?

NCT00781482 is currently withdrawn. Last updated 26 February 2016.

Last reviewed 2016-02-26 · How we verify

NCT00781482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Withdrawn Phase 4 Last updated 26 February 2016

What this trial tests

Phase 4 trial testing eszopiclone, zolpidem, placebo in Healthy. Withdrawn.

Quick facts

Lead sponsor	Kettering Health Network
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Sites	1 location across United States

Drugs / interventions tested

eszopiclone, zolpidem, placebo — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Kettering Health Network

Who can join

Adults 18 to 35, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will compare the interactions of a placebo and two FDA-approved sleeping medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in the brain. We want to show that we can use positron emission tomography images to measure the binding of these medications to the receptors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Kettering Health Network trials

Trials by the same sponsor.

NCT07157865 — Comparing Prism Adaptation Training With and Without TENS to Minimize Unilateral Spatial Neglect · NA · recruiting
NCT06150443 — COMET-AOA: Median Nerve Stiffness in Mild-Moderate CTS With OMT & Conservative Therapy · NA · completed
NCT06058910 — Bilistick Point-of-care System 2.0 Bilirubin Validation · completed
NCT04282720 — SurgiMend Mesh at the Hiatus · NA · completed
NCT03867539 — Exparel and Education to Avoid Opioids After Carpal Tunnel Release · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00781482 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kettering Health Network
Last refreshed: 26 February 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00781482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing